| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ... The Lancet 389 (10066), 255-265, 2017 | 4642 | 2017 |
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer GV Scagliotti, P Parikh, J Von Pawel, B Biesma, J Vansteenkiste, ... Journal of clinical oncology 26 (21), 3543-3551, 2008 | 4283 | 2008 |
| Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer T Winton, R Livingston, D Johnson, J Rigas, M Johnston, C Butts, ... New England Journal of Medicine 352 (25), 2589-2597, 2005 | 2321 | 2005 |
| Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small-cell lung cancer previously treated with platinum-containing … FV Fossella, R DeVore, RN Kerr, J Crawford, RR Natale, F Dunphy, ... Journal of Clinical Oncology 18 (12), 2354-2362, 2000 | 1730 | 2000 |
| Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial KS Albain, RS Swann, VW Rusch, AT Turrisi, FA Shepherd, C Smith, ... The Lancet 374 (9687), 379-386, 2009 | 1664 | 2009 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1646 | 2015 |
| Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest … K Kelly, J Crowley, PA Bunn Jr, CA Presant, PK Grevstad, CM Moinpour, ... Journal of Clinical Oncology 19 (13), 3210-3218, 2001 | 1554 | 2001 |
| Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab DR Gandara, SM Paul, M Kowanetz, E Schleifman, W Zou, Y Li, ... Nature medicine 24 (9), 1441-1448, 2018 | 1086 | 2018 |
| Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group … KS Albain, VW Rusch, JJ Crowley, TW Rice, AT Turrisi 3rd, JK Weick, ... Journal of Clinical Oncology 13 (8), 1880-1892, 1995 | 1083 | 1995 |
| Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer RVN Lord, J Brabender, D Gandara, V Alberola, C Camps, M Domine, ... Clinical Cancer Research 8 (7), 2286-2291, 2002 | 995 | 2002 |
| Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. AJ Wozniak, JJ Crowley, SP Balcerzak, GR Weiss, CH Spiridonidis, ... Journal of Clinical Oncology 16 (7), 2459-2465, 1998 | 807 | 1998 |
| Proposal for classifying the acute emetogenicity of cancer chemotherapy. PJ Hesketh, MG Kris, SM Grunberg, T Beck, JD Hainsworth, G Harker, ... Journal of Clinical Oncology 15 (1), 103-109, 1997 | 787 | 1997 |
| Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non–small-cell lung cancer: SWOG S0023 K Kelly, K Chansky, LE Gaspar, KS Albain, J Jett, YC Ung, DHM Lau, ... Journal of clinical oncology 26 (15), 2450-2456, 2008 | 696 | 2008 |
| Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret … AA Garcia, H Hirte, G Fleming, D Yang, DD Tsao-Wei, L Roman, ... Journal of Clinical Oncology 26 (1), 76-82, 2008 | 679 | 2008 |
| Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with … FR Hirsch, M Varella-Garcia, J McCoy, H West, AC Xavier, P Gumerlock, ... J clin oncol 23 (28), 6838-6845, 2005 | 666 | 2005 |
| Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ... Journal of clinical oncology 25 (19), 2747-2754, 2007 | 664 | 2007 |
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors L Gandhi, DR Camidge, M Ribeiro de Oliveira, P Bonomi, D Gandara, ... Journal of clinical oncology 29 (7), 909-916, 2011 | 654 | 2011 |
| Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment PN Lara Jr, R Higdon, N Lim, K Kwan, M Tanaka, DHM Lau, T Wun, ... Journal of clinical oncology 19 (6), 1728-1733, 2001 | 633 | 2001 |
| Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 PN Lara Jr, R Natale, J Crowley, HJ Lenz, MW Redman, JE Carleton, ... Journal of clinical oncology 27 (15), 2530, 2009 | 623 | 2009 |
| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 604 | 2018 |
